Literature DB >> 24128595

Single-agent liposomal all-trans-retinoic Acid as initial therapy for acute promyelocytic leukemia: 13-year follow-up data.

Preetesh Jain1, Hagop Kantarjian1, Elihu Estey2, Sherry Pierce1, Jorge Cortes1, Gabriel Lopez-Berestein3, Farhad Ravandi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24128595      PMCID： PMC4103408          DOI： 10.1016/j.clml.2013.08.004

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  9 in total

1.  Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.

Authors:  Vikram Mathews; Biju George; Ezhilarasi Chendamarai; Kavitha M Lakshmi; Salamun Desire; Poonkuzhali Balasubramanian; Auro Viswabandya; Rajashekar Thirugnanam; Aby Abraham; Ramachandran Velayudhan Shaji; Alok Srivastava; Mammen Chandy
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

Review 2.  Acute promyelocytic leukemia can be treated successfully without cytotoxic chemotherapy.

Authors:  Farhad Ravandi
Journal:  Oncology (Williston Park)       Date:  2011-07       Impact factor: 2.990

Review 3.  How to manage acute promyelocytic leukemia.

Authors:  J-Q Mi; J-M Li; Z-X Shen; S-J Chen; Z Chen
Journal:  Leukemia       Date:  2012-03-16       Impact factor: 11.528

4.  Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia.

Authors:  E H Estey; F J Giles; H Kantarjian; S O'Brien; J Cortes; E J Freireich; G Lopez-Berestein; M Keating
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

5.  Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine.

Authors:  E Estey; P F Thall; S Pierce; H Kantarjian; M Keating
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

6.  Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.

Authors:  Apostolia-Maria Tsimberidou; Maribel Tirado-Gomez; Michael Andreeff; Susan O'Brien; Hagop Kantarjian; Michael Keating; Gabriel Lopez-Berestein; Elihu Estey
Journal:  Leuk Lymphoma       Date:  2006-06

7.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

Authors:  Farhad Ravandi; Eli Estey; Dan Jones; Stefan Faderl; Susan O'Brien; Jackie Fiorentino; Sherry Pierce; Deborah Blamble; Zeev Estrov; William Wierda; Alessandra Ferrajoli; Srdan Verstovsek; Guillermo Garcia-Manero; Jorge Cortes; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

8.  Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers.

Authors:  Bulent Ozpolat; Gabriel Lopez-Berestein; Peter Adamson; ChauHwei J Fu; Anthony H Williams
Journal:  J Pharm Pharm Sci       Date:  2003 May-Aug       Impact factor: 2.327

9.  All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.

Authors:  Zhi-Xiang Shen; Zhan-Zhong Shi; Jing Fang; Bai-Wei Gu; Jun-Min Li; Yong-Mei Zhu; Jing-Yi Shi; Pei-Zheng Zheng; Hua Yan; Yuan-Fang Liu; Yu Chen; Yang Shen; Wen Wu; Wei Tang; Samuel Waxman; Hugues De Thé; Zhen-Yi Wang; Sai-Juan Chen; Zhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-24       Impact factor: 11.205
  9 in total
  7 in total

Review 1.  The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target.

Authors:  Xiao Zhen Zhou; Kun Ping Lu
Journal:  Nat Rev Cancer       Date:  2016-06-03       Impact factor: 60.716

Review 2.  Contemporary treatment of APL.

Authors:  Elizabeth H Cull; Jessica K Altman
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

3.  Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.

Authors:  Kazuhiro Koikawa; Shin Kibe; Futoshi Suizu; Nobufumi Sekino; Nami Kim; Theresa D Manz; Benika J Pinch; Dipikaa Akshinthala; Ana Verma; Giorgio Gaglia; Yutaka Nezu; Shizhong Ke; Chenxi Qiu; Kenoki Ohuchida; Yoshinao Oda; Tae Ho Lee; Babara Wegiel; John G Clohessy; Nir London; Sandro Santagata; Gerburg M Wulf; Manuel Hidalgo; Senthil K Muthuswamy; Masafumi Nakamura; Nathanael S Gray; Xiao Zhen Zhou; Kun Ping Lu
Journal:  Cell       Date:  2021-08-12       Impact factor: 66.850

4.  Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer.

Authors:  Shuo Wei; Shingo Kozono; Lev Kats; Morris Nechama; Wenzong Li; Jlenia Guarnerio; Manli Luo; Mi-Hyeon You; Yandan Yao; Asami Kondo; Hai Hu; Gunes Bozkurt; Nathan J Moerke; Shugeng Cao; Markus Reschke; Chun-Hau Chen; Eduardo M Rego; Francesco Lo-Coco; Lewis C Cantley; Tae Ho Lee; Hao Wu; Yan Zhang; Pier Paolo Pandolfi; Xiao Zhen Zhou; Kun Ping Lu
Journal:  Nat Med       Date:  2015-04-13       Impact factor: 53.440

5.  Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways.

Authors:  Xiaolan Lian; Yu-Min Lin; Shingo Kozono; Megan K Herbert; Xin Li; Xiaohong Yuan; Jiangrui Guo; Yafei Guo; Min Tang; Jia Lin; Yiping Huang; Bixin Wang; Chenxi Qiu; Cheng-Yu Tsai; Jane Xie; Ziang Jeff Gao; Yong Wu; Hekun Liu; Xiao Zhen Zhou; Kun Ping Lu; Yuanzhong Chen
Journal:  J Hematol Oncol       Date:  2018-05-30       Impact factor: 17.388

Review 6.  Phosphorylation-Dependent Pin1 Isomerization of ATR: Its Role in Regulating ATR's Anti-apoptotic Function at Mitochondria, and the Implications in Cancer.

Authors:  Yetunde Makinwa; Phillip R Musich; Yue Zou
Journal:  Front Cell Dev Biol       Date:  2020-04-30

Review 7.  Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine.

Authors:  Raquel Ferreira; Joseph Napoli; Tariq Enver; Liliana Bernardino; Lino Ferreira
Journal:  Nat Commun       Date:  2020-08-26       Impact factor: 14.919
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.